Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye
Biologics applying antibodies against IgE, IL-5, IL-5 receptor α, IL-4 receptor α, and IL-13 have dramatically improved recent treatment outcomes in allergic diseases including asthma, rhinitis, and atopic dermatitis. However, these drugs have not been approved for ocular allergic diseases such as a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893022001204 |
| _version_ | 1827975245909196800 |
|---|---|
| author | Ken Fukuda Tatsuma Kishimoto Tamaki Sumi Kenji Yamashiro Nobuyuki Ebihara |
| author_facet | Ken Fukuda Tatsuma Kishimoto Tamaki Sumi Kenji Yamashiro Nobuyuki Ebihara |
| author_sort | Ken Fukuda |
| collection | DOAJ |
| description | Biologics applying antibodies against IgE, IL-5, IL-5 receptor α, IL-4 receptor α, and IL-13 have dramatically improved recent treatment outcomes in allergic diseases including asthma, rhinitis, and atopic dermatitis. However, these drugs have not been approved for ocular allergic diseases such as allergic conjunctivitis, vernal keratoconjunctivitis, and atopic keratoconjunctivitis. Although the putative mechanisms suggest that these drugs should have beneficial effects in patients with ocular allergies and some studies have reported such beneficial effects, various adverse ocular symptoms have also been observed in clinical trials and off-label use studies. Since ocular allergic diseases have distinct pathogeneses, each biologic drug must be examined regarding specific effects on each ocular allergy. For example, IgE-mediated type 1 hypersensitivity plays a critical role in allergic conjunctivitis. By contrast, T cells and eosinophilic and non-IgE-mediated type 2 inflammation play important roles in vernal keratoconjunctivitis. Allergists must fully understand the effects of each drug on the eye. This review outlines both potential therapeutic and adverse effects of various biologics on allergic diseases of the eye. |
| first_indexed | 2024-04-09T20:08:31Z |
| format | Article |
| id | doaj.art-3b400253805e462ea3239f8ea7f7517f |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-04-09T20:08:31Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-3b400253805e462ea3239f8ea7f7517f2023-04-01T08:45:54ZengElsevierAllergology International1323-89302023-04-01722234244Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eyeKen Fukuda0Tatsuma Kishimoto1Tamaki Sumi2Kenji Yamashiro3Nobuyuki Ebihara4Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kochi, Japan; Corresponding author. Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Ophthalmology and Visual Science, Juntendo University Urayasu Hospital, Tokyo, JapanBiologics applying antibodies against IgE, IL-5, IL-5 receptor α, IL-4 receptor α, and IL-13 have dramatically improved recent treatment outcomes in allergic diseases including asthma, rhinitis, and atopic dermatitis. However, these drugs have not been approved for ocular allergic diseases such as allergic conjunctivitis, vernal keratoconjunctivitis, and atopic keratoconjunctivitis. Although the putative mechanisms suggest that these drugs should have beneficial effects in patients with ocular allergies and some studies have reported such beneficial effects, various adverse ocular symptoms have also been observed in clinical trials and off-label use studies. Since ocular allergic diseases have distinct pathogeneses, each biologic drug must be examined regarding specific effects on each ocular allergy. For example, IgE-mediated type 1 hypersensitivity plays a critical role in allergic conjunctivitis. By contrast, T cells and eosinophilic and non-IgE-mediated type 2 inflammation play important roles in vernal keratoconjunctivitis. Allergists must fully understand the effects of each drug on the eye. This review outlines both potential therapeutic and adverse effects of various biologics on allergic diseases of the eye.http://www.sciencedirect.com/science/article/pii/S1323893022001204Allergic conjunctivitisAtopic keratoconjunctivitisBiologicsCytokineVernal keratoconjunctivitis |
| spellingShingle | Ken Fukuda Tatsuma Kishimoto Tamaki Sumi Kenji Yamashiro Nobuyuki Ebihara Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye Allergology International Allergic conjunctivitis Atopic keratoconjunctivitis Biologics Cytokine Vernal keratoconjunctivitis |
| title | Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye |
| title_full | Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye |
| title_fullStr | Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye |
| title_full_unstemmed | Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye |
| title_short | Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye |
| title_sort | biologics for allergy therapeutic potential for ocular allergic diseases and adverse effects on the eye |
| topic | Allergic conjunctivitis Atopic keratoconjunctivitis Biologics Cytokine Vernal keratoconjunctivitis |
| url | http://www.sciencedirect.com/science/article/pii/S1323893022001204 |
| work_keys_str_mv | AT kenfukuda biologicsforallergytherapeuticpotentialforocularallergicdiseasesandadverseeffectsontheeye AT tatsumakishimoto biologicsforallergytherapeuticpotentialforocularallergicdiseasesandadverseeffectsontheeye AT tamakisumi biologicsforallergytherapeuticpotentialforocularallergicdiseasesandadverseeffectsontheeye AT kenjiyamashiro biologicsforallergytherapeuticpotentialforocularallergicdiseasesandadverseeffectsontheeye AT nobuyukiebihara biologicsforallergytherapeuticpotentialforocularallergicdiseasesandadverseeffectsontheeye |